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Paradoxical Enhancement of Atherosclerosis by Probucol Treatment in
Apolipoprotein E–deficient Mice
 



















Dietary administration of probucol (0.5%, wt/wt) efficiently










) by 40%, with decreases in high
density lipoprotein (HDL) and apoAI by 70 and 50%, re-
spectively. Paradoxically, however, aortic atherosclerotic

















 mice, and the
lesions were two to four times larger and more mature re-
 















Histologically, lesions in probucol-treated mice contained
increased fibrous materials and cells other than foam cells,
and were commonly associated with focal inflammation
and aneurysmal dilatation. Probucol treatment also acceler-








 mice fed an athero-
genic diet, indicating that the adverse effect is not depen-
dent on the complete absence of apoE. Furthermore, mice
lacking apoE and apoAI have plasma lipoprotein profiles








 mice, but do
not have accelerated plaque development. Thus, the en-
hanced atherosclerosis in the probucol-treated animals is
unlikely to be caused by the reduction of HDL and apoAI
levels. Our data indicate that a reduction in plasma choles-






























Atherosclerosis results from multiple complex interactions be-
tween injurious stimuli and the responses of the arterial wall
that occur in a hyperlipidemic environment. The cytotoxic ac-
tivity of oxidized low density lipoproteins (LDL) and peroxi-
dized lipids may damage the endothelium and contribute to
the initiation of atherogenesis as a result of free radical chain
reactions (1, 2). The administration of hypolipidemic drugs
and antioxidants is, therefore, a rational means of trying to
prevent the development of atherosclerosis.
Probucol is a drug that has both cholesterol-lowering and
antioxidant effects. With a free radical–scavenging phenol
structure and high lipid solubility, probucol is carried within li-
poprotein particles, and essentially prevents the oxidation of
LDL (3). Probucol is able to reduce LDL levels via an LDL re-
ceptor–independent pathway (4), since the drug can effectively
reduce cholesterol levels in homozygous LDL receptor–defi-
cient patients. Probucol reduces HDL levels to an even greater
degree. In addition, probucol reduces the storage of lipid in
macrophages (5), and has been shown to reverse xanthomas in
some severely hypercholesterolemic patients (5).
In experimental animal models, probucol reduced lesion






 rabbits in some, but not all experi-
ments (6–9). Probucol also inhibited atherosclerosis induced
by high-fat, high-cholesterol diet in the nonhuman primate
(10), but not in cholesterol-fed rabbits (11). The effects of pro-
bucol on human patients are likewise not well established. For
example, a recent human trial (Probucol Quantitative Regres-
sion Swedish Trial, PQRST) has shown the ineffectiveness of
probucol in retarding femoral artery atherosclerosis, despite
the presence of a drug-induced reduction in cholesterol levels
and antioxidant effects (12, 13).
In this study, we have tested the effects of probucol on mice
 








mice have spontaneously elevated plasma cholesterol levels,
and develop atherosclerosis even on a regular low-fat/low-cho-
lesterol diet (14, 15). The time-dependent progression of ath-








 mice leads to lesions simi-
lar in histopathology to those observed in humans and other
species (16, 17). Our results show that probucol effectively













Animals and experimental design.
 
Mice were bred in-house and main-
tained on regular chow. Four sets of dietary probucol treatments (0.5/
100 g chow) were conducted using age-matched (within 10 d of birth)
and sex-matched mice. Body weight and plasma lipid levels were
monitored before the treatment, and then at every 4 wk.





















 99% C57BL/6J (B6) genetic background as a
result of backcrossing B6:129 F1 heterozygotes (18) to B6 for six gen-
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Abbreviations used in this paper:
 
 FPLC, fast protein liquid chroma-








experiment 1a, nine 2-mo-old female mice were fed chow with probu-
col for 3 mo, and nine were fed regular chow. In experiment 1b, six








 mice were on the









 mice were on the probucol-free diet for 3 mo before
death.
In experiment 1c, 2-mo-old mice with mixed 129 and C57BL/6J








 mice (five male,









 mice (six male, eight female) received regular chow
for 2 mo. All males and five females were killed after 2 mo of treat-
ment. Two female mice were fed the probucol diet for an additional

























mice. Six female and six male controls were fed regular chow, and
four female and six male controls were fed probucol-containing diet
for 2 mo.








 heterozygotes were generated by








 mice with wild-type B6 ani-








 females were fed an atherogenic diet
(see below) with probucol for 3 mo, and six were fed the atherogenic
diet without probucol.
Mice deficient for apolipoprotein AI (apoAI) were also in B6 ge-
netic background generated by backcrossing 129/B6 F1 heterozygotes

















mice to generate mice doubly deficient for apoE and apoAI. 





All of the regular mouse chow used in experiment 1 had
4.5% fat (wt/wt) and 0.022% cholesterol, although the supplier var-
ied. All mice were fed relevant control diet without probucol for 2 wk
before commencement of the experiment. Plasma cholesterol levels
were measured to ensure that no animals were included that had lev-
els substantially different from the others in their group.
In experiment 1a, the regular control diet (C1) was prepared (No.
11708; Dyets, Inc., Bethlehem, PA), based on their AIN-93 diet to
contain 0.022% cholesterol. Probucol was kindly supplied by (Daiichi
Pharmaceuticals, Tokyo, Japan). The main protein and fat sources of
AIN-93 are casein and soybean oil. In experiment 1b, regular control
chow, C2 (based on CE2, CLEA JAPAN, Inc., Tokyo, Japan), and
C2 with 0.5% (wt/wt) probucol were provided by Chugai Pharmaceu-
ticals Co. (Gotenba, Japan). The main protein and fat sources of C2
are fish meal and soybean oil. In experiment 1c, the probucol (gener-
ously provided by Merrell-Dow Pharmaceuticals Inc., Indianapolis,
IN) was dissolved in ethanol and added to the regular control diet,
C3, (No. 5012; Ralston Purina Co., St. Louis, MO) to achieve a final
concentration of 0.5% (wt/wt). The ethanol was allowed to evaporate
by drying in air for 48 h. The main protein and fat sources of C3 are
soy protein, casein, and animal fat.
An atherogenic diet containing 15.8% fat, 1.25% cholesterol, and
0.5% cholic acid was prepared (Dyet No. 11724), based on AIN-93.




In experiment 1b, the plasma probucol levels
were measured on individual samples by Dr. Y. Ohba (Chugai Phar-
maceuticals Co.). In experiment 1c, probucol levels in pooled plasma
were measured in the laboratory of Dr. D. Steinberg (University of
California, San Diego), using high performance liquid chromatogra-
phy (4).
 
Plasma lipid and lipoprotein analysis.
 
Blood samples were ob-
tained from animals fasted overnight by retroorbital bleeding, as
previously described (14). Total plasma cholesterol and triglyceride
levels were determined enzymatically with reagents from Sigma
Chemical Co. (St. Louis, MO), or from Wako Bioproducts (Rich-
mond, VA). HDL cholesterol was determined after removing apoli-
poprotein B–containing particles by a magnesium/dextran sulfate









diluted 1:3 with phosphate-buffered saline before the precipitation
 
procedure. All the measurements were done in duplicates. The
apoAI amounts in plasma samples were compared by densitometric
analysis of Coomassie blue–stained or silver-stained bands after non-
reducing SDS-polyacrylamide gel electrophoresis (21). Relative lev-
els of plasma apoAI, apoAIV, and apoE were also measured densito-
metrically using a chemiluminescent procedure (ECL kit; Amersham
Corp., Arlington Heights, IL) on Western blots using rabbit antisera
against mouse apoAI or apoAIV (gifts from Dr. H. DeSilva, Univer-
sity of North Carolina, Charlotte), and goat anti–human apoE antise-
rum (Calbiochem Corp., San Diego, CA). Total lipoproteins from
pooled plasma were isolated by ultracentrifugation with density ad-


















were loaded in each lane and subjected to SDS-PAGE using a 4–20%
gradient gel; staining was with Coomassie blue. The size distributions
of plasma lipoproteins were analyzed by fast protein liquid chroma-
tography (FPLC) using a Superose 6 HR10/30 column (Pharmacia





l). 0.5-ml fractions were collected at a flow rate of 0.4 ml/min.
 
Evaluation of atherosclerotic lesions.
 
Mice were killed with an
overdose of Avertin (Aldrich Chemical Co., Milwaukee, WI). The heart
and the arterial tree were perfused with phosphate-buffered paraform-
aldehyde (4%, pH 7.4) under physiological pressure. Serial cryosec-
tions of the proximal aorta and the aortic sinus were made and stained
with Sudan IVB (Fisher Scientific Co., Pittsburgh, PA), and counter-
stained with hematoxylin. Hematoxylin and eosin–stained sections
were used for histological evaluations. Average lesion sizes of four sec-
tions, spanning the region from the very proximal aorta to the point in
the aortic sinus that contains three complete valve leaflets, were used
for the morphometric evaluations based on the methods by Paigen et
al. (22). Whole aortas, from the descending aorta to the iliac bifurca-
tion, were isolated from each mouse, and all the fatty tissue in the ad-
ventitia was stripped away with fine dissection forceps. The gross image
of the aortas was photographed (M420 microscope; Wild Heerbrugg In-
struments, Inc., Farmingdale, NY) and the lesion sizes were measured
by quantitating the lesion-covered areas on the aortic vessel walls (NIH








 test of unpaired two-sample means was
used to compare plasma lipid levels and aortic lesion sizes (as loga-
rithms) in the probucol-treated mice with the corresponding values of




Probucol efficiently reduces plasma cholesterol levels in apoE-
deficient mice.
 
We observed no significant changes in body
weight or general health of the mice fed 0.5% (wt/wt) probucol
in their diet compared to mice fed the control diet. The total
cholesterol levels found in animals 4 wk after commencement
of probucol treatment were stably maintained throughout the
remainder of all experiments. Comparisons of plasma lipid levels
between probucol-treated and -untreated mice at the end of
each treatment protocol are summarized in Table I. In experi-









mals, plasma cholesterol levels in the probucol-treated females















Plasma total cholesterol in all four male mice in experiment
1b, also reduced by an average of 30% compared to their lev-









with untreated mice were not significant, partly because of the
small number of mice used. In experiment 1c, carried out with
mice of B6:129 mixed genetic background, total plasma choles-








 female mice were














































 0.0005). Reduction in plasma cholesterol
levels in probucol-treated male animals having this genetic
background was similarly significant (data not shown). The hy-
pocholesterolemic effect of probucol treatment was also ob-








) mice fed a diet containing high
fat and high cholesterol (experiment 2). The total plasma cho-


















to their prefeeding levels (data not shown), while the increase




80 mg/dl. Thus, probucol efficiently lowers the plasma cho-
lesterol levels in apoE-deficient animals.
Cholesterol levels in both apolipoprotein B–containing li-
poproteins and HDL were reduced in the probucol-treated an-
imals, although the extent of reduction of the cholesterol in
these two classes of lipoproteins was different in animals of the
















 mice, 89% of









 mice, 92 (experiment 1c) to 95% (experiment 1b) of
the reduction was in the cholesterol of apolipoprotein B–con-









 0.01) in experiments 1a and 1c, but no difference
was observed in experiment 1b. The variability in the HDL-C
values in these experiments may be a consequence of variabil-
ity in the removal of VLDL-IDL (intermediate density lipo-
protein) fraction by precipitation when VLDL-IDL choles-
terol is high. We note, however, that the observed reduction in
HDL cholesterol after probucol treatment is supported by the
results of FPLC analysis presented in Fig. 1 below. No signifi-
cant difference between treated and untreated animals in tri-
glyceride levels was observed in any of the experiments.










































 4) in males. The
plasma probucol levels in mice treated with probucol for 2 wk






mg/ml (n 5 3) in the apoE2/2
mice, and 6.761.2 mg/ml (n 5 5) in the apoE1/1 or 1/2 mice.
Thus, the probucol levels reached in the apoE2/2 mice were
equivalent to those reported in human patients (20–90 mg/ml)
with familial hypercholesterolemia on conventional therapeu-
tic doses (1 g/d) (23).
Marked reduction in HDL cholesterol and plasma apoAI
levels by probucol treatment. To evaluate the reduction in each
class of lipoprotein by probucol more precisely, the size distri-
butions of plasma lipoproteins in the probucol-treated and
-untreated female mice in experiments 1a and 2 were deter-
mined by FPLC (Fig. 1). Over 90% of the cholesterol in both
probucol-treated and -untreated apoE2/2 mice was in the
large remnant particles that elute in the VLDL and IDL range
(fractions 14–25, Fig. 1 A, open circles) for untreated mice as
reported previously (14). Cholesterol in the VLDL-IDL frac-
tions of the probucol-treated apoE2/2 mice (fractions 14–25,
Fig. 1 B, filled circles) was z 40% that of the nontreated mice.
Reduction in HDL cholesterol (fractions 28–31, Fig. 1, A and
B) was more marked, by z 70% in both apoE2/2 mice fed
regular diet, and in the apoE1/2 mice fed the atherogenic
diet. Reduction by probucol in particles in the IDL range (by
31%, fractions 19–25 in Fig. 1 B) was also similar in the
apoE1/2 mice fed the atherogenic diet to that in the apoE2/2
mice fed the regular chow, while the reduction in VLDL was
less (13%) and variable at different times (data not shown).
Parallel to the reduction in HDL levels, a substantial de-
crease in total plasma apoAI levels was observed in both control
(apoE1/1 or apoE1/2) and apoE2/2 mice. Fig. 2 illustrates
this reduction in total plasma apoAI levels by silver-stained
nonreducing SDS-PAGE. The reduction determined by densi-
tometry of apoAI in pooled plasma was the same (52% reduc-
tion by densitometry scanning) in both the apoE2/2 mice and
the control (apoE1/1 or apoE1/2) mice fed regular chow
(Fig. 2). ApoAI levels measured by Western blot and densi-
tometry in individual plasma samples of probucol-treated
mice from experiment 1a and experiment 2 were 50610 and
57616%, respectively, that of mice fed the control diets.
ApoAIV amounts in probucol-treated plasma were also re-
duced (to 77627 and 71620%, respectively, of untreated), but
the difference was not statistically significant. ApoE amounts
in high fat–fed apoE1/2 mice did not differ in the probucol-
Table I. The Effects of Probucol on Plasma Lipid Levels
Exp Diet ApoE Sex n BW TC TG HDLC ApoAI Probucol
1a C1 2/2 F 9 2463 406671 88642 23611 10066
C1 1 P 2/2 F 9 2562 248649§ 69634 1368‡ 50610§ ND
1b C2 2/2 F 5 2163 5426101 63613 1466 ND
C2 1 P 2/2 F 6 2362 330678‡ 67612 966 ND 49.6615.7
C2 2/2 M 3 2862 6376104 121648 2867 ND
C2 1 P 2/2 M 4 2763 479691 77625 31611 ND 56.263.8
1c C3 1/* F 6 2266 83622 67618 68620 100
C3 1 P 1/* F 4 2161 1768§ 77611 1566§ 48 6.761.2
C3 2/2 F 8 2262 5736101 79624 53623 100
C3 1 P 2/2 F 8 2561 194654§ 79627 2168‡ 48 53.4616.4
2 HF 1/2 F 6 2161 215647 2065 ND 10066
HF 1 P 1/2 F 6 2261 170618 2167 ND 57616‡ ND
Diets are with (1 P) or without probucol in control chow (C1, C2, C3) or in high-fat diet (HF). Control animals 1/* in experiment 1c included both
wild-type and heterozygous animals. F, females; M, males; Exp, experiment; BW, body weight (g); TC, total plasma cholesterol (mg/dl); HDLC, HDL
cholesterol (mg/dl); TG, triglyceride (mg/dl). ApoAI levels are expressed as a mean value of the respective control as 100. Probucol levels are in
mg/ml. ND, not determined. ‡0.001 , P , 0.05, §P , 0.001, against the corresponding levels in untreated animals by Student’s t test.
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treated and untreated groups. Apolipoprotein compositions
after SDS-PAGE of lipoprotein fractions in the probucol-
treated mice did not show any obvious differences from those
in the untreated mice except for the above noted parallel re-
ductions of apoAI, apo AIV, apoB48 in the apoE 2/2 mice,
and the control mice treated with probucol (data not shown).
Enhancement of atherosclerotic lesion development by pro-
bucol treatment. A total of 57 probucol-treated and -untreated
apoE2/2 mice were examined for the development of athero-
sclerosis in their aortic sinus and proximal aorta of the animals
after a standard protocol, essentially as described by Paigen et
al. (22). Experiment 1a was the largest single experiment, with
18 age-matched apoE2/2 females fed regular chow with (nine
animals) or without (nine animals) probucol. The mean lesion
sizes of the individual animals (Fig. 3 A) shows that the lesions
in all of the nine mice treated with probucol in this experiment
were larger than any of the lesions in the nine untreated mice
with no overlap. The logarithmic mean area was three times
larger in the probucol-treated mice compared to that in the un-
treated mice (335,000 vs. 98,000 mm2, P , 1026). Table II sum-
marizes the results from experiments 1b and 1c. Experiments
1b and 1c are directly comparable to experiment 1a, except
that they are with smaller numbers of males and females. Ad-
ditionally, experiment 1c was with mice having a mixed B6:129
genetic background. In all experiments, the probucol-treated
mice had larger plaques than the untreated mice (Table II).
Female mice had larger lesions on both the regular diet and
the probucol diet than did male mice at the same age. The
mice in experiment 1c had smaller lesions than mice in experi-
ments 1a and 1b, partly because the former mice were
younger, and partly because they had a mixed B6:129 genetic
background compared to the latter group of mice which were
backcrossed onto the inbred B6 genetic background. The P
values of the lesion sizes in the probucol-treated groups com-
pared to those of respective control groups were all significant
except in males in experiment 1c (P 5 0.059 was not signifi-
cant). Thus, without exception, the data from these two addi-
Figure 1. Lipoprotein FPLC profiles with (A) pooled plasma (50 ml) 
from apoE2/2 mice on a regular diet, and (B) pooled plasma 100 ml 
from apoE1/2 mice on the atherogenic diet. Filled and open circles 
indicate probucol-treated animals and untreated animals, respec-
tively.
Figure 2. Plasma total apoAI levels determined by silver staining af-
ter nonreducing SDS-PAGE. 1 ml of plasma pooled from three to five 
animals was applied to each lane. Only the bands corresponding to 
apoAI are shown. Lane 1, apoAI 2/2 and apoE 2/2 untreated; 
lanes 2 and 5, apoE 1/1 (normal) untreated; lane 3, apoE 1/2 un-
treated; lane 4, apoE 2/2 untreated; lane 6, apoE 2/2 probucol-
treated; lane 7, apoE 1/1 (normal) probucol-treated. All the animals 
had a mixed C57BL/6J:129 genetic background.
Figure 3. The effect of probucol on the size of atherosclerotic lesions. 
(A) apoE2/2 mice on regular diet, and (B) apoE1/2 mice on the 
atherogenic diet. Each point represents the mean lesion size of four 
sections from each mouse. Filled circles represent probucol-treated 
mice, and open circles represent untreated mice. Horizontal bars and 
the numbers represent the logarithmic mean value in mm2 of lesion 
size from each group of mice. The vertical bars represent the range of 
logarithmic mean6SD in logarithmic scale.
2862 Zhang et al.
tional experiments also demonstrate that probucol treatment
enhances atherosclerotic plaque development in apoE2/2
mice regardless of sex, age, genetic background, and the
source of the diet.
To test whether the adverse effect of probucol was the re-
sult of the complete lack of apoE in the 2/2 mice, we also ex-
amined heterozygous apoE1/2 mice which produce about
half the normal level of apoE. ApoE1/2 mice do not develop
lesions when maintained on regular chow diet, but consistently
do so when fed an atherogenic diet (24). Accordingly, the
apoE1/2 females were fed the atherogenic diet with or with-
out probucol. The results are presented in Fig. 4 B and in Ta-
ble II as experiment 2. We found that the mice consuming the
atherogenic diet containing 0.5% (wt/wt) probucol again had
larger lesions (P , 0.003). These results establish, therefore,
that the enhanced plaque development does not depend on
the complete lack of apoE. The data also indicate that probu-
col not only accelerates the growth of existing plaques of
apoE2/2 mice, but also accelerates plaque formation in
apoE1/2 mice.
To determine whether accelerated lesion progression by
probucol in apoE-deficient mice occurs only in the aortic sinus
and in the proximal aorta, we carried out lesional histomor-
phometry in the descending area from the aortic arch to the il-
iac bifurcation. Examination of five probucol-treated female
mice in experiment 1b, in which treatment began at 3 mo of
age when lesions are not usually detected in the descending
aorta (16), revealed that all had greater number and larger
plaques in the descending aorta than in the four untreated ani-
mals, which had only a few small lesions. The areas covered by
the lesions in the descending aorta of the probucol-treated
mice (5.461.0 mm2) were four times those in the untreated
mice (1.460.5 mm2). Thus, enhancement of atherosclerosis by
probucol occurs throughout the aortic tree of apoE mice.
Lesions in probucol-fed mice are more mature than those in
control mice. Histological examination was carried out by
light microscope of the serial sections of aortic sinus and proxi-
mal aorta. As illustrated in Fig. 4, sections even at low magnifi-
cation revealed that, compared to the atherosclerotic lesions in
nontreated mice (Fig. 4 A), the lesions in mice treated with
probucol for 3 mo (Fig. 4, B–D) were not only larger but also
more mature. The lesions in the nontreated mice were mainly
composed of foam cells with small acellular areas adjacent to
the media (Fig. 4 A). Lesions in the probucol-treated mice
contained fewer lipids, but were more fibrous and contained
cells other than foam cells. Inflammation within plaques as
well as in adventitia was evident (Fig. 4 B). Strikingly, large an-
eurysmal areas were frequently present in the probucol-
treated animals with the B6 genetic background. Thus, we
found that seven of the nine probucol-treated mice in experi-
ment 1a had large aneurysmal dilatation in the aortic sinus, as
illustrated in Fig. 4, C and D. In contrast, none of the nine un-
treated control group had large aneurysmal dilatations; one
had a sign of media thinning in the similar area. Thinning and
weakening of the media commonly occurs at or near a coro-
nary ostium, and typically involves large outpockets filled with
plaque materials, calcific deposits, necrosis, and inflammatory
cells (Fig. 4 C). Extensive fibrosis in adventitial tissues indi-
cates chronic inflammation surrounding the aneurysm (Fig.
4 D, lower right quadrant). Despite their large sizes, these an-
eurysms appear to be asymptomatic. Aneurysms of this type
are often noted in older apoE2/2 mice. Whether their fre-
quent occurrence at the relatively young age of 5 mo in the
present experiment is a primary effect of the probucol treat-
Table II. Mean Lesion Sizes in Proximal Aortic Area of ApoE-deficient Mice
Exp Mice Diet
Age (mo) Mean lesion area*
PSex Start End Probucol-treated Untreated
mm2 3 1023
1a 2/2, B6 C1 F 2 5 335 (246–455), n 5 9 98 (75–126), n 5 9 , 1026
1b 2/2, B6 C2 F 3 6 532 (345–822), n 5 5 263 (184–377), n 5 5 0.024
M 4 7 603 (564–644), n 5 3 402 (353–457), n 5 3 0.017
1c 2/2, B6:129 C3 F 2 4 85 (50–146), n 5 5 25 (15–42), n 5 6 0.0045
M 2 4 23 (16–33), n 5 5 12 (6–21), n 5 6 0.059
2 1/2, B6 HF F 2 5 74 (48–113), n 5 6 24 (14–42), n 5 6 0.003
F, females; M, males; HF, high fat; Exp, experiment. C1, C2, and C3 are regular mouse chow containing 4.5% fat and 0.022% cholesterol (see Meth-
ods). Ages of mice are in months at the beginning and the end of diet treatment. *Mean lesion areas are logarithmic means; the areas one logarithmic
standard deviation on either side of the means are in parentheses.
Figure 4. Comparison of aortic lesions of probucol-treated and nontreated apoE 2/2 mice. A and B show cross-sections of the aorta near the 
aortic sinus from the 5-mo-old mice fed control diet and probucol diet, respectively. Sudan IVB and hematoxylin staining; 345. (C) Thinning of 
media near a coronary ostium representing aneurysmal dilatation commonly seen in probucol diet–fed mice; 345. (D) Cross-section of proximal 
aorta from another mouse showing an aneurysm filled with plaque material. Evaluation of nearby sections show that this aneurysm originated 
near a ostium similar to C. Extensive fibrosis in the area surrounding aneurysmal outpockets is present; 345. (E) A plaque in proximal aorta 
from an untreated mouse showing collection of intact foam cells. A cellular area is present adjacent to media; 390. (F) A plaque in a probucol-
treated mouse contains punctate lipid droplets, a fibrous cap, and focal inflammatory infiltration; 390. G and H show cross-sections of the prox-
imal aorta from 4-mo-old apoE 2/2 mice with a B6:129 mixed genetic background fed regular diet and probucol diet, respectively. Hematoxylin 
and eosin staining, 3110.
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ment itself, or is secondary to the increased plaque growth, is
currently unknown.
At higher magnifications, the lesions in the untreated mice
showed a dense accumulation of lipid-filled foam cells near the
surface, and the lipid present within the plaque was largely in-
tracellular (Fig. 4 E). A well-defined fibrous cap was not
present. In contrast, the lesions in the probucol-treated mice
showed diffuse and punctate staining for lipids, suggesting that
the lipid was mainly extracellular (Fig. 4 F). Sparse collections
of intact foam cells were seen near the surface. Well-defined
fibrous caps and cholesterol clefts were present. Focal inflam-
mation within the plaques was common in the probucol-
treated animals (Fig. 4 F). In 4-mo-old mice with a mixed ge-
netic background, both on a regular diet (Fig. 4 G) and on a
probucol diet (Fig. 4 H) for 2 mo, the lesions were character-
ized mainly by foam cell depositions without fibrous cap for-
mation. Notable difference, however, between the lesions in
the probucol-treated and the -untreated mice of this group was
that a significant number of mononuclear cells was commonly
seen on or near the surface of lesions in the probucol-treated
mice (Fig. 4 H), but rarely in the untreated mice (Fig. 4 G).
This type of accumulation of mononucleated cells was not seen
in the mature lesions of either regular diet or drug-treated
mice. Taken together, these comparisons suggest that the
lesions in the probucol-treated mice are in general more ma-
ture than in the untreated mice, with more inflammatory cells
present in the lesions of the treated animals.
Reduced HDL cholesterol and apoAI are not causes of the
adverse effects of probucol. Since the levels of plasma HDL
cholesterol have been shown to be inversely associated with
atherosclerosis in various studies (25), the adverse effect on
the development of atherosclerosis seen with probucol treat-
ment of apoE-deficient mice may be the result of the dramatic
reduction of HDL cholesterol that accompanies the treatment.
To test this possibility, we intercrossed apoE2/2 mice with
apoAI2/2 mice that lack apoAI and have markedly reduced
plasma HDL cholesterol levels (19). To minimize the effects of
other genetic loci, the mice with the apoE mutation and with
the apoAI mutation were individually backcrossed towards B6
before the intercross. The total plasma cholesterol levels (Ta-
ble III) in female and male mice lacking both apoAI and apoE
(aaee) were significantly lower (by z 40%) than those in the
apoE2/2 mice (AAee). The HDL cholesterol levels in the
aaee mice were also significantly lower, as shown by enzymic
measurements (Table III), and by FPLC analysis (data not
shown), in which . 95% of cholesterol in the aaee mice was in
particles in the VLDL range; cholesterol in the HDL range
was almost undetectable. Note that the levels and distributions
of plasma cholesterol in the AAee mice with probucol are very
similar to those in the aaee mice.
The mean lesion areas in the aaee mice were, however, not
significantly different from those in the AAee mice (Table III).
Because the B6 backcrossed mutants do not breed well, we
were only able to evaluate a limited number of aaee mice at
4 mo of age during the last 2 yr. Furthermore, during this pe-
riod, the colony environment, including air handling and bed-
ding materials, was changed because of factors beyond our
control. Consequently, the data in Table III show wider varia-
tions in lesion sizes in all the mice than normal (results varied
from one animal to the other by over 10-fold). Nevertheless, in
all these tests, the lesions in aaee mice were fewer than those in
the AAee (in contrast to the threefold larger lesions seen in the
AAee mice that had reduced levels of apoAI when treated
with probucol). Together, the results make it very unlikely that
the enhanced lesion formation accompanying probucol treat-
ment is caused by the reduced HDL cholesterol and plasma
apoAI levels.
Discussion
In this study, the effects of probucol on plasma cholesterol lev-
els and atherosclerotic lesion development in apoE2/2 mice
were evaluated using mice with either a B6 inbred genetic
background or with a mixed B6:129 genetic background. As
expected from previous studies in humans and in other ani-
mals (including mice), probucol markedly reduced the total
cholesterol, HDL cholesterol, and total plasma apoAI levels in
all the apoE2/2 mice studied. Probucol also effectively re-
duced the extent of dietary-induced hypercholesterolemia in
apoE1/2 mice in response to the atherogenic diet.
Probucol reduces LDL cholesterol levels by enhancing the
removal of LDL (26), and it has been hypothesized that probu-
col achieves this reduction by incorporating into LDL parti-
cles, and thereby altering their structures (3). This effect is
thought to be mediated through an LDL receptor–indepen-
dent pathway, since probucol is effective in lowering LDL cho-
lesterol in homozygous familial hypercholesterolemic patients,
and in homozygous WHHL rabbits, both of which lack the
LDL receptor. In apoE2/2 mice, hypercholesterolemia is the
result of accumulation of VLDL and chylomicron remnants as
a consequence of the lack of apoE, a ligand having a high affin-
ity for LDL and other receptors. We found here that probucol
significantly reduces the levels of the atherogenic remnant par-
ticles in mice lacking apoE, and that this hypolipidemic effect
occurs to a similar extent (21–66% reduction) to the effects of
probucol in WHHL rabbits (24% reduction) (4, 6) with similar
plasma levels of the drug. Consequently, our data demonstrate
that probucol is capable of reducing plasma cholesterol levels
through apoE-independent pathway(s).
Various modes of action of probucol have been described
in different species (27–31). In the rat, its hypocholesterolemic
effect appears to result predominantly from a decrease in
absorption of cholesterol (28), whereas in humans and mice
it results mainly from the stimulation of catabolic excretion
through the bile (27, 28). Tawara et al. (27) have shown that
probucol treatment in normal mice results in an accelerated
Table III. Effect of ApoAI Deficiency on Plasma Lipid
Levels and Atherosclerotic Lesion Development in
ApoE-deficient Mice
Sex Genotype (n) TC TG HDLC Mean lesion area§
mg/dl mg/dl mg/dl mm2 3 1023
Females AAee (14) 4676115 72625 34614 106 (50–227), n 5 8
aaee (12) 315667* 66628 17611* 60 (27–133), n 5 8
Males AAee (12) 560681 117647 43618 67 (37–122), n 5 12
aaee (8) 3886159‡ 78633‡ 13610* 48 (43, 54), n 5 2
TC, total plasma cholesterol; TG, triglyceride; HDLC, HDL choles-
terol. *P , 0.001, ‡0.001 , P , 0.05. §Mean lesion areas are logarithmic
means; the areas one logarithmic standard deviation on either side of
the means are in parentheses.
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clearance of [14C]cholesterol-derived radioactivity from the
circulation, accompanied by an increased fecal radioactivity ex-
cretion and an increase in hepatic cholesterol 7a-hydroxylase
activity. Cholesterol synthesis in the drug-treated mice was not
changed. Our preliminary observation, that cholesterol 7a-
hydroxylase mRNA levels are significantly elevated by probu-
col in apoE2/2 mice (unpublished observation), agrees with
these findings, and suggests that probucol lowers cholesterol,
at least partly, by increasing bile excretion in these mice de-
spite the fact that plasma cholesterol-containing lipoproteins
cannot be efficiently taken up by the liver in the absence of
apoE. It is possible that the reduction in plasma cholesterol in
the apoE2/2 mice results from a reduced output of lipopro-
teins secondary to an increased rate of conversion of choles-
terol to bile acids in the liver.
Contrary to what might be expected from the cholester-
ol-lowering effect of probucol, however, the present study
showed that probucol not only did not retard atherosclerosis
in our apoE2/2 mice, but actually accelerated lesional devel-
opment. This paradoxical result was consistently seen in three
independent experiments carried out at different times, with
different sources of diet, with animals of different genetic
backgrounds, and with both male and female mice. The probu-
col treatment enhanced atherosclerotic lesions in animals in
which treatment commenced at 2 mo of age, an age at which
minimal lesions are found in the aortas. The treatment also en-
larged the lesions in animals that were 4 mo old at the start
of treatment, an age when full-blown atherosclerotic lesions
covered with fibrous caps are already present. The combined
P value for the effect of probucol on lesions is considerably
less than 1026.
The inverse relationship between the cholesterol level and
lesion size that we have observed in our apoE2/2 mice after
probucol treatment has not been reported in any other previ-
ous experiments, although its ineffectiveness in retarding fem-
oral artery atherosclerosis has been observed in a human trial
(12), and lack of effect on atheroma formation was also re-
ported in some of the animal experiments (8, 11). Our obser-
vation of enhanced atherosclerosis by probucol in apoE-defi-
cient mice is further surprising in view of probucol’s strong
antioxidant activity. A number of antioxidants have been
shown to have antiatherogenic effects (32) and Tangirala et al.
(33) reported that treatment with N,N9-diphenyl 1,4-phe-
nylenediamine, a different class of antioxidant compound from
probucol, was effective in reducing atherosclerosis in apoE2/2
mice fed a high-fat diet containing 0.15% cholesterol (33).
The marked reduction of apoAI and HDL cholesterol must
be considered as one possible explanation for the accelerated
atherosclerosis by probucol in the apoE-deficient mice. Our
observation that mice lacking both apoAI and apoE do not
show an accelerated development of atherosclerosis (although
their HDL cholesterol levels are markedly reduced), however,
argues that this is unlikely to be the major explanation of our
findings.
Although the mechanisms underlying the enhancement we
observed are not known, probucol may be affecting directly
the atherogenic process in the apoE-deficient mice. For exam-
ple, others have suggested that the subtle balance of plasma
and tissue antioxidants may be altered in the presence of high
amounts of probucol in the plasma (34). Here, we have noted
an increased mononuclear cell attachment to the atheroscle-
rotic lesions of the apoE2/2 mice after probucol treatment;
this attachment was more evident in the nonmatured foam cell
lesions than in the matured fibrous cap lesions. An accumula-
tion of monocytes on the surface of the endothelium after
probucol treatment has also been reported in rats (35). These
several findings suggest that probucol might be inducing
monocyte attractant factors in the vessel wall, which could be
expected to accelerate the atherogenic process. Furthermore,
we commonly observed focal inflammation within mature
plaques and inflammatory cell–induced alterations of the ad-
ventitia in the aorta of the probucol-treated animals. Interest-
ingly, we also observed that mice fed probucol for 3 mo had
significantly larger spleens than untreated mice (0.1660.05 vs.
0.0960.02 g in apoE2/2 mice in experiment 1a, n 5 9, P ,
0.01; 0.1360.02 vs. 0.0960.01 g in apoE1/2 in experiment 2,
n 5 6, P , 0.005). Histologically, the spleens were indicative of
reactive splenomegaly. No proinflammatory changes at a tis-
sue level associated with high concentration of probucol have
been described previously. Further studies are necessary to
evaluate the influence of probucol on inflammatory processes
in these strains of mice.
Probucol has a high affinity for lipids, and its rate of clear-
ance is dependent on the rate of clearance of plasma lipid.
Even after probucol treatment, the cholesterol level in the
apoE2/2 mice (200 mg/dl) is 10-fold higher than the level in
the probucol-treated apoE1/1 or apoE1/2 mice (20 mg/dl).
Concomitantly, there is about a 10-fold higher plasma probu-
col level in the apoE2/2 mice than in the apoE1/1 or
apoE1/2 mice, so that the plasma probucol level is propor-
tional to the plasma cholesterol level in these mice. The
plasma probucol levels in the apoE2/2 mice (50 mg/ml) were
comparable to those seen in treated WHHL rabbits, or in hu-
man patients administered the conventional therapeutic dose.
The possibility needs to be considered, however, that the
chronic presence of such high levels of probucol in plasma
(which can be reached in the presence of hyperlipidemia in
mice) might be harmful. Further studies of the effects of
probucol on atherogenesis in other mouse models, such as the
LDL receptor–deficient mice (36) or the human apolipopro-
tein B transgenic mice (37, 38), should be undertaken to clarify
whether the adverse effect is related to the lack or insuffi-
ciency of apoE-mediated mechanism(s) in the apoE2/2 mice,
or to the high-fat diet which is fed to the apoE1/2 mice. Ben-
eficial effect of probucol in WHHL rabbits, and its detrimental
effect in apoE-deficient mice, is a species-specific difference.
Whatever the cause of the actual existence of this proves to be,
our data suggest the need for further investigations of the ef-
fects of long-term probucol treatment, particularly in mark-
edly hyperlipidemic patients.
In summary, we have demonstrated that probucol mark-
edly enhances the development of atherosclerosis in the mice
lacking apoE, and in mice having reduced levels of apoE in
spite of its ability to cause significant reductions in total plasma
cholesterol. Our data indicate that the measurement of total
plasma cholesterol levels may not in itself be sufficient to doc-
ument the effectiveness of probucol treatment.
Acknowledgments
We thank S. Kim, J. Tyson, and B. Oswald for technical help, Drs. D.
Steinberg and Y. Ohba for determining plasma probucol levels in the
mice, Drs. S. Ishibashi and H. deSilva for providing us the cholesterol
7a-hydroxylase cDNA probe and antisera, Dr. T. Kodama for his
2866 Zhang et al.
help in arranging the supply of probucol, and Drs. O. Smithies and J.
Osada for their critical reading of this manuscript.
This work was supported by National Institutes of Health re-
search grant HL-42630 to N. Maeda.
References
1. Schwartz, C.J., A.J. Valente, E.A. Sprague, J.L. Kelley, and R.M. Nerem.
1991. The pathogenesis of atherosclerosis: an overview. Clin. Cardiol. 14:I1–I16.
2. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the
1990s. Nature (Lond.). 362:801–809.
3. Parthasarathy, S., S.G. Young, J.L. Witztum, R.C. Pittmann, and D.
Steinberg. 1986. Probucol inhibits oxidative modification of low density lipo-
protein. J. Clin. Invest. 77:641–644.
4. Naruszewicz, M., T.E. Carew, R.C. Pittman, J.L. Witztum, and D. Stein-
berg. 1984. A novel mechanism by which probucol lowers low density lipopro-
tein levels demonstrated in the LDL receptor-deficient rabbit. J. Lipid Res. 25:
1206–1213.
5. Yamamoto, A., Y. Matsuzawa, S. Yokoyama, T. Funahashi, T. Yama-
mura, and B. Kishino. 1986. Effects of probucol on xanthomata regression in fa-
milial hypercholesterolemia. Am. J. Cardiol. 57:29H–35H.
6. Kita, T., Y. Nagano, M. Yokode, K. Ishii, N. Kume, A. Ooshima, H.
Yoshida, and C. Kawai. 1987. Probucol prevents the progression of atheroscle-
rosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial
hypercholesterolemia. Proc. Natl. Acad. Sci. USA. 84:5928–5931.
7. Nagano, Y., T. Nakamura, Y. Matsuzawa, M. Cho, Y. Ueda, and T. Kita.
1992. Probucol and atherosclerosis in Watanabe heritable hyperlipidemic rab-
bit—long-term antiatherogenic effect and effects on established plaques. Ath-
erosclerosis. 92:131–140.
8. Daugherty, A., B.S. Zweifel, and G. Shonfeld. 1991. The effects of probu-
col on the progression of atherosclerosis in mature Watanabe heritable hyper-
lipidemic rabbits. Br. J. Pharmacol. 103:1013–1018.
9. Braesen, J.H., U. Beisiegel, and A. Niendolf. 1995. Probucol inhibits not
only the progression of atherosclerotic disease, but causes a different composi-
tion of atherosclerotic lesions in WHHL-rabbits. Virchows Arch. 426:179–188.
10. Sasahara, M., E.W. Raines, A. Chait, T.E. Carew, D. Steinberg, P.W.
Wahl, and R. Ross. 1994. Inhibition of hypercholesterolemia-induced athero-
sclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclero-
sis related to resistance of LDL to oxidation? J. Clin. Invest. 94:155–164.
11. Stein, Y., O. Stein, B. Delplanque, J.D. Fesmire, D.M. Lee, and P.
Alaupovic. 1989. Lack of effect of probucol on atheroma formation in choles-
terol-fed rabbits kept at comparable plasma cholesterol levels. Atherosclerosis.
75:145–155.
12. Walldius, G., U. Erikson, A.G. Olsson, L. Bergstrand, K. Hadell, J. Jo-
hansson, L. Kaijser, C. Lassvik, J. Molgaard, and S. Nilsson. 1994. The effect of
probucol on femoral atherosclerosis: the Probucol Quantitative Regression
Swedish Trial (PQRST). Am. J. Cardiol. 74:875–883.
13. Regnstrom, J., G. Walldius, S. Nilsson, L.S. Elinder, J. Johansson, J.
Molgaard, I. Holme, A.G. Olsson, and J. Nilsson. 1996. The effect of probucol
on low density lipoprotein oxidation and femoral atherosclerosis. Atherosclero-
sis. 125:217–229.
14. Zhang, S.H., R.L. Reddick, J.A. Piedrahita, and N. Maeda. 1992. Spon-
taneous hypercholesterolemia and arterial lesions in mice lacking apolipopro-
tein E. Science (Wash. DC). 258:468–471.
15. Plump, A.S., D.J. Smith, T. Hayek, K. Aalto-Setala, A. Walsh, J.G. Ver-
stuyft, E.M. Rubin, and J.L. Breslow. 1992. Severe hypercholesterolemia and
atherosclerosis in apolipoprotein E-deficient mice created by homologous re-
combination in ES cells. Cell. 71:343–353.
16. Reddick, R.L., S.H. Zhang, and N. Maeda. 1994. Atherosclerosis in
mice lacking apolipoprotein E: evaluation of lesional development and progres-
sion. Arterioscler. Thromb. 14:141–147.
17. Nakashima, Y., A.S. Plump, E.W. Raines, J.L. Breslow, and R. Ross.
1994. ApoE-deficient mice develop lesions of all phases of atherosclerosis
throughout the arterial tree. Arterioscler. Thromb. 14:133–140.
18. Piedrahita, J.A., S.H. Zhang, J.R. Hagaman, P.M. Oliver, and N.
Maeda. 1992. Generation of mice carrying a mutant apolipoprotein E gene in-
activated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. USA.
89:4471–4475.
19. Williamson, R., D. Lee, J. Hagaman, and N. Maeda. 1992. Marked re-
duction of high density lipoprotein cholesterol in mice genetically modified to
lack apolipoprotein A-I. Proc. Natl. Acad. Sci. USA. 89:7134–7138.
20. Warnick, G.R., J. Benderson, and J.J. Albers. 1982. Dextran sulfate-
Mg21 precipitation procedure for quantitation of high-density-lipoprotein cho-
lesterol. Clin. Chem. 28:1379–1382.
21. France, D.S., T.E. Hughes, R. Miserendino, J.A. Spirito, J. Babiak, J.B.
Eskesen, C. Tapparelli, and J.R. Paterniti, Jr. 1989. Nonimmunochemical quan-
titation of mammalian apolipoprotein AI in whole serum or plasma by nonre-
ducing gel electrophoresis. J. Lipid. Res. 30:1997–2004.
22. Paigen, B., A. Morrow, P.A. Holmes, D. Mitchell, and R.A. Williams.
1987. Quantitative assessment of atherosclerotic lesions in mice. Atherosclero-
sis. 68:231–240.
23. Baker, S.G., B.I. Joffe, D. Mendelsohn, and H.C. Seftel. 1982. Treat-
ment of homozygous familial hypercholesterolaemia with probucol. S. Afr.
Med. J. 62:7–11.
24. Zhang, S.H., R.L. Reddick, B. Burkey, and N. Maeda. 1994. Diet-induced
atherosclerosis in mice heterozygous and homozygous for apolipoprotein E
gene disruption. J. Clin. Invest. 94:937–945.
25. Gordon, D.J., and B.M. Rifkind. 1989. High-density lipoprotein: the
clinical implications of recent studies. N. Eng. J. Med. 321:1311–1316. 
26. Nestel, P.J., and T. Billington. 1981. Effects of probucol on low density
lipoprotein removal and high density lipoprotein synthesis. Atherosclerosis. 38:
203–209.
27. Tawara, K., M. Tomikawa, and Y. Abiko. 1986. Mode of action of
probucol in reducing serum cholesterol in mice. Jpn. J. Pharmacol. 40:123–133.
28. Beynen, A.C. 1986. Discrepancies between the outcome of animal and
human studies on the mode of action of probucol. Atherosclerosis. 61:249–251.
29. Atmeh, R.F., M.J. Stewart, D.E. Boag, C.J. Packard, A.R. Lorimer, and
J. Shepherd. 1983. The hypolipidemic action of probucol: a study of its effects
on high and low density lipoproteins. J. Lipid Res. 24:588–595.
30. Hayek, T., T. Chjek-Shaul, A. Wals, N. Azrolan, and J.L. Breslow. 1991.
Probucol decreases apolipoprotein AI transport rate and increases high density
lipoprotein cholesterol ester fractional catabolic rate in control and human apo-
lipoprotein AI transgenic mice. Arterioscler. Thromb. 11:1295–1302.
31. Steinberg, D. 1986. Studies on the mechanism of action of probucol.
Am. J. Cardiol. 57:16H–21H.
32. Bjorkham, I., A. Henrucksson-Freyschuss, O. Breuer, U. Diczfalusy, L.
Berglund, and P. Henrikson. 1991. The antioxidant butylated hydroxytoluene
protects against atherosclerosis. Arterioscler. Thromb. 11:15–22.
33. Tangirala, R.K., F. Casanada, E. Millwe, J.L. Witztum, D. Steinberg,
and W. Palinski. 1995. Effect of the antioxidant N,N9-diphenyl 1,4-phenylenedi-
amine (DPPD) on atherosclerosis in apoE-deficient mice. Arterioscler.
Thromb. 15:1625–1630.
34. Elinder, L.S., K. Hadell, J. Johansson, J. Molgaard, I. Holme, A.G. Ols-
son, and G. Walldius. 1995. Probucol treatment decreases serum concentrations
of diet-derived antioxidants. Arterioscler. Thromb. Vasc. Biol. 15:1057–1063.
35. Snankar, R., J.D. Sallis, H. Stanton, and R. Thomson. 1989. Influence of
probucol on early experimental atherogenesis in hypercholesterolemic rats.
Atherosclerosis. 78:91–97.
36. Ishibashi, S., J.L. Goldstein, M.S. Brown, J. Herz, and D.K. Barns. 1994.
Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipo-
protein receptor-negative mice. J. Clin. Invest. 93:1885–1893.
37. Purcell-Huynh, D.A., R.V. Farese, Jr., D.F. Johnson, L.M. Flynn, V.
Pierotti, D.L. Newland, M.F. Linton, D.A. Sanan, and S.G. Young. 1995. Trans-
genic mice expressing high levels of human apolipoprotein B develop severe
atherosclerotic lesion in response to a high-fat diet. J. Clin. Invest. 95:2246–
2257.
38. Callow, M.J., J. Verstuyft, R. Tangirala, W. Palinski, and E.M. Rubin.
1995. Atherogenesis in transgenic mice with human apolipoprotein B and lipo-
protein (a). J. Clin. Invest. 96:1639–1646.
